Palbociclib: Breast cancer drugs list & full guide
Palbociclib is an innovative targeted therapy and the first-in-class inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). It functions by blocking specific proteins that allow cancer cells to divide uncontrollably, effectively halting tumor growth.
This medication has revolutionized the treatment of hormone receptor-positive (HR+) and HER2-negative breast cancer, significantly extending progression-free survival. On Unifarm, you will find a list of available brand-name drugs and high-quality generics containing this active substance.
Indications
- Treatment of locally advanced or metastatic breast cancer (HR+/HER2-).
- First-line therapy: In combination with an aromatase inhibitor (e.g., letrozole) in postmenopausal women.
- Second-line therapy: In combination with fulvestrant in women who have received prior endocrine therapy.
Dosage and administration
Taken orally (capsules/tablets) strictly with food to ensure optimal absorption.
Dosing Regimen (28-day cycle):
- Recommended Dose: 125 mg once daily for 21 consecutive days.
- Break: 7 days off treatment before starting a new cycle.
In case of toxicity (especially hematologic), the physician may reduce the dose to 100 mg or 75 mg.
